Neurovance Inks $7M

Neurovance has raised $7 million in Series A1 financing led by existing investor Novartis Venture Fund. The company will use the money for continued development of its norepinephrine and dopamine-preferring reuptake inhibitor. Neurovance was spun out of Euthymics Bioscience, and is based in Cambridge, Mass.

North AmericaUSBriefs